List of Excipients in Branded Drug VITRAKVI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare Pharmaceuticals Inc	VITRAKVI	larotrectinib	50419-390	GELATIN	2036-08-15
Bayer HealthCare Pharmaceuticals Inc	VITRAKVI	larotrectinib	50419-390	TITANIUM DIOXIDE	2036-08-15
Loxo Oncology Inc	VITRAKVI	larotrectinib	71777-390	GELATIN	2036-08-15
Loxo Oncology Inc	VITRAKVI	larotrectinib	71777-390	TITANIUM DIOXIDE	2036-08-15

Vitrakvi Excipient Strategy and Commercial Opportunities for Larotrectinib

Last updated: August 26, 2026

Vitrakvi (larotrectinib) uses a dual oral dosage-form strategy: capsules for standard administration and a 20 mg/mL oral solution for pediatric patients, patients with swallowing limitations, and dose-adjustment needs. The principal excipient opportunities are pediatric palatability, preservative and packaging optimization, global formulation harmonization, and differentiated liquid-dose delivery. Commercial expansion is constrained by the small, biomarker-selected NTRK fusion population and by the ability of generic manufacturers to replicate conventional oral formulations.

What is Vitrakvi and how is it administered?

Vitrakvi is an oral, tumor-agnostic therapy for adults and children with solid tumors harboring an NTRK gene fusion without a satisfactory alternative treatment or whose disease has progressed following treatment. The active ingredient is larotrectinib sulfate, equivalent to larotrectinib [1].

The FDA-approved dosage forms are:

Dosage form	Strength	Principal use
Capsule	25 mg	Oral administration where swallowing is practical
Capsule	100 mg	Standard adult and older pediatric dosing
Oral solution	20 mg/mL	Pediatric use, dysphagia, dose flexibility

The recommended dose is 100 mg twice daily in adults and children with a body-surface area of at least 1.0 m². Pediatric patients with a body-surface area below 1.0 m² receive 100 mg/m² twice daily, subject to the product-label maximum [1].

The liquid formulation is commercially important because NTRK fusion cancers occur across pediatric and adult populations. The oral solution also enables dose modification without splitting or manipulating capsules.

What excipients are used in Vitrakvi capsules and oral solution?

The Vitrakvi excipient platform separates solid-dose stability from liquid-dose usability.

Vitrakvi capsule excipients

The capsules contain conventional hard-gelatin shell materials and colorants. The product labeling identifies gelatin, titanium dioxide, and black iron oxide among the capsule components. The printing system contains conventional pharmaceutical ink constituents [1].

The capsule strategy prioritizes:

• Chemical and physical stability of larotrectinib.
• Reliable content uniformity at 25 mg and 100 mg strengths.
• Recognizable strength differentiation.
• Compatibility with standard high-speed capsule manufacturing.
• Low excipient complexity for supply-chain control.

Capsule excipients are unlikely to provide a strong standalone commercial moat. Generic manufacturers can usually reproduce hard-gelatin capsules, color systems, and standard printing technologies unless the originator has secured enforceable formulation, manufacturing, or presentation claims.

Vitrakvi oral-solution excipients

The oral solution contains anhydrous citric acid, disodium edetate, methylparaben, propylene glycol, purified water, and sucralose, according to the U.S. prescribing information [1].

Excipient	Formulation function
Anhydrous citric acid	pH adjustment and acidic-medium control
Disodium edetate	Chelation of trace metals and stability support
Methylparaben	Antimicrobial preservation
Propylene glycol	Cosolvent and solubility aid
Purified water	Aqueous vehicle
Sucralose	Sweetening and palatability improvement

This composition indicates a conventional aqueous solution approach rather than a suspension or lipid-based delivery system. The formulation is designed to keep larotrectinib dissolved, reduce metal-catalyzed degradation risk, limit microbial growth, and improve acceptability for children.

Why is the Vitrakvi oral solution commercially important?

The oral solution is the strongest excipient-related commercial asset in the Vitrakvi product line. Its value arises from patient access and dosing flexibility rather than from a novel delivery mechanism.

Pediatric administration

Children may require body-surface-area-based dosing, making a 20 mg/mL solution more practical than multiple capsule combinations. Liquid administration also avoids capsule swallowing difficulties and allows caregivers to measure individualized doses.

The main commercial sensitivities are:

• Taste masking.
• Dose-measurement accuracy.
• Oral-syringe compatibility.
• Stability after opening.
• Microbiological control.
• Caregiver handling.
• Packaging volume and portability.

A competing liquid product could differentiate through improved taste, a lower-viscosity vehicle, reduced dosing volume, a longer in-use period, or a ready-to-use presentation that minimizes preparation steps.

Dose modification

Larotrectinib labeling includes dose modifications for adverse reactions and coadministration with certain CYP3A inhibitors or inducers [1]. A liquid dosage form allows more precise dose reduction than capsule-only therapy.

This is commercially relevant in a rare-disease setting because treatment can continue through manageable toxicity when the formulation supports accurate dose adjustments. The value is strongest for small children and patients receiving prolonged treatment.

Dysphagia and administration flexibility

Adults with advanced cancer may have dysphagia, mucositis, feeding-tube requirements, or impaired oral intake. A liquid format can expand practical use, although administration through feeding tubes requires product-specific compatibility and should not be assumed without supporting data.

A formulation company could pursue tube-compatible packaging, validated administration instructions, and a dedicated oral syringe as part of an integrated product offering.

What formulation opportunities exist around Vitrakvi?

The largest opportunities are incremental improvements to the oral solution and age-appropriate delivery. A new product would need to demonstrate a meaningful clinical, handling, stability, or adherence advantage.

Improved palatability

Sucralose provides sweetness, but sweetness alone does not establish acceptable taste for pediatric oncology patients. Larotrectinib’s taste profile, aftertaste, and interaction with flavor systems could support development of:

• More effective flavor masking.
• Lower-intensity sweetener systems.
• Fruit or confectionery flavor systems.
• Taste-masking polymers or ion-exchange approaches.
• Lower-volume, higher-concentration presentations.

A more concentrated product would require new safety, dose-measurement, stability, and administration data. It could reduce bottle size and shipping costs, but dosing errors would become a greater risk.

Preservative alternatives

Methylparaben is a conventional preservative. Potential alternatives include potassium sorbate, sodium benzoate, benzyl alcohol-free systems, or preservative-free unit-dose packaging. Each option creates regulatory and technical tradeoffs involving pH, antimicrobial effectiveness, tolerability, container closure, and in-use stability.

A preservative-free presentation could be attractive for neonates, very young children, or patients with preservative sensitivity. Unit-dose packaging would increase manufacturing and packaging costs and could reduce the commercial advantage unless it materially improves safety or institutional use.

Excipient reduction

A simplified formula could reduce the number of excipient-related regulatory questions and improve global registration. Potential targets include:

• Replacing propylene glycol if pediatric exposure limits or local requirements create concern.
• Reducing or removing methylparaben.
• Replacing color or flavor components.
• Using a self-preserving pH system.
• Improving solubility so fewer cosolvents are required.

The current label does not identify a clinical safety signal specific to these excipients. The commercial case for reformulation would therefore depend on pediatric acceptability, geographic requirements, or manufacturing economics rather than on a broad safety problem.

Packaging and device integration

The oral syringe, bottle, adapter, and closure system are part of the effective product. Opportunities include:

• Low-residual-volume oral syringes.
• Child-resistant but caregiver-friendly closures.
• Unit-dose sachets or stick packs.
• Bottle designs that reduce sediment or dose loss.
• Digital dose guides linked to body-surface-area calculations.
• Packaging optimized for cold-chain-independent distribution.

These assets may be protected through device, packaging, or combination-product claims even when the excipient composition itself is conventional.

How does Vitrakvi compare with competing targeted oral therapies?

Vitrakvi differs from many targeted oncology drugs because it was developed for a rare genomic driver across multiple tumor types rather than for one organ-specific indication.

Commercial factor	Vitrakvi	Typical targeted oral oncology product
Biomarker	NTRK gene fusion	Often mutation- or receptor-specific
Patient population	Rare, cross-tumor	Frequently larger disease-defined population
Pediatric relevance	Material	Variable
Liquid formulation value	High because of pediatric dosing	Variable
Capsule substitution risk	Moderate to high after loss of exclusivity	Depends on formulation complexity
Diagnostic dependence	Requires validated NTRK testing	Usually requires companion or complementary testing
Main formulation opportunity	Palatable, stable oral liquid	Often extended release, solubility, or combination delivery

Repotrectinib, marketed as Augtyro, is a direct competitive reference in the NTRK inhibitor segment, although it has a broader kinase profile and a different product formulation. Entrectinib, marketed as Rozlytrek, also competes in NTRK fusion-positive disease and has indications involving ROS1-positive cancers [2,3]. Vitrakvi’s liquid presentation gives it a distinct pediatric and dose-flexibility position.

What FDA regulatory status and exclusivity apply to Vitrakvi?

The FDA granted accelerated approval to Vitrakvi in November 2018 for NTRK fusion-positive solid tumors. The approval was later converted to traditional approval after confirmatory evidence supported the clinical benefit [4].

Key U.S. regulatory facts include:

Regulatory item	Vitrakvi status
Active ingredient	Larotrectinib sulfate
NDA	211710
Initial FDA approval	November 26, 2018
FDA pathway	Accelerated approval, later traditional approval
Therapeutic category	Tumor-agnostic targeted oncology
Pediatric formulation	20 mg/mL oral solution
Orphan-drug relevance	NTRK fusion-positive solid tumors

The product received orphan-drug designation for the relevant rare disease population. Orphan exclusivity generally runs for seven years from approval for the designated indication, subject to statutory limitations and possible challenges [5]. New chemical entity exclusivity generally runs for five years from approval, although the effective timing of generic filing and approval also depends on listed patents and FDA litigation rules.

When does Vitrakvi lose exclusivity and face generic entry?

Vitrakvi’s practical loss-of-exclusivity date depends on three separate protections:

1. Regulatory exclusivity.
2. Orange Book-listed patents.
3. Litigation outcomes and settlement terms.

The five-year NCE period from the 2018 approval has elapsed. Orphan exclusivity, if applicable to the approved indication and not otherwise interrupted, extends beyond the NCE period. Generic applicants may also face listed patents covering the active ingredient, formulation, method of use, or other aspects of the product.

A generic capsule is technically easier to develop than a liquid formulation. The oral solution creates additional work involving:

• Q1/Q2 formulation similarity.
• Preservative effectiveness.
• Assay and degradation products.
• Container-closure compatibility.
• In-use stability.
• Dose-delivery-device performance.
• Flavor and excipient qualification.

Those requirements can delay launch but do not necessarily prevent approval. A generic sponsor may initially target capsules, then develop the oral solution after establishing commercial demand.

What patent and Paragraph IV risks affect Vitrakvi?

A generic or follow-on applicant seeking approval before relevant patent expiry may submit a Paragraph IV certification against Orange Book-listed patents. The brand company can file patent litigation within the statutory period, triggering the applicable regulatory stay under the Hatch-Waxman framework [6].

For Vitrakvi, the principal patent-risk categories are:

Active-ingredient and compound patents

These patents can provide the strongest barrier if they cover larotrectinib or a pharmaceutically acceptable salt with a later expiration date than the NCE period.

Formulation patents

Formulation claims could cover:

• The 20 mg/mL aqueous solution.
• Specific pH ranges.
• Propylene glycol or chelator systems.
• Preservative combinations.
• Flavor or taste-masking systems.
• Stability profiles.
• Container-closure configurations.

Conventional excipients alone generally provide limited protection. Patent strength improves when the formulation claims a defined composition linked to unexpected stability, dissolution, palatability, or bioavailability results.

Method-of-use patents

Method claims may cover treatment of NTRK fusion-positive cancers, particular tumor types, pediatric patients, or dosing regimens. Their enforceability against generic use depends on the approved labeling, skinny-label strategy, induced-infringement evidence, and the scope of the asserted claims.

The current Orange Book should be used to verify Vitrakvi’s listed patents, expiration dates, pediatric extensions, and any litigation certifications before making a launch-date forecast [7].

Which companies control Vitrakvi commercialization and licensing?

Vitrakvi originated with Loxo Oncology. Bayer entered a global development and commercialization collaboration with Loxo in 2013. Eli Lilly acquired Loxo Oncology in 2019, while Bayer retained its rights under the collaboration arrangement [8,9].

The commercial structure creates two relevant strategic points:

• Bayer controls the marketed Vitrakvi product and commercial execution under its rights.
• Lilly retains an economic interest through the pre-existing collaboration framework.

This structure can affect licensing discussions involving regional rights, lifecycle management, formulation partnerships, and pediatric presentation development.

What generic launch scenarios exist for Vitrakvi?

Three launch scenarios are commercially plausible:

Scenario	Product entry	Likely market effect
Capsule-first	25 mg and 100 mg capsules	Early price erosion in adult use
Solution-follow-on	Equivalent 20 mg/mL oral solution	Greater pediatric and caregiver competition
Broad portfolio entry	Capsules plus solution	Faster substitution and payer pressure

The capsule-first scenario is the most technically straightforward. The oral-solution scenario may require more development work but could capture a higher-value segment because caregivers and pediatric specialists may prioritize dosing reliability and tolerability over the lowest unit price.

Biosimilar risk is not relevant to Vitrakvi because larotrectinib is a small-molecule drug, not a biologic. The relevant competitive pathways are abbreviated new drug applications, 505(b)(2) applications for modified formulations, and, outside the United States, national generic or hybrid applications.

Key Takeaways

• Vitrakvi’s main excipient asset is its 20 mg/mL oral solution, not its conventional hard-gelatin capsules.
• The solution uses citric acid, disodium edetate, methylparaben, propylene glycol, purified water, and sucralose.
• Pediatric palatability, dosing accuracy, preservative strategy, packaging, and feeding-tube usability offer the clearest lifecycle-management opportunities.
• A reformulated liquid could compete through better taste, lower volume, preservative reduction, longer in-use stability, or improved device integration.
• Capsule generic entry is likely to be technically simpler than oral-solution substitution.
• Vitrakvi has no biosimilar risk because larotrectinib is a small molecule.
• Patent and launch analysis must distinguish NCE exclusivity, orphan exclusivity, Orange Book patents, and Paragraph IV litigation.
• Bayer commercializes Vitrakvi under its collaboration structure with Loxo Oncology, now part of Eli Lilly.

FAQs about Vitrakvi excipients and formulation strategy

Is Vitrakvi oral solution suitable for pediatric patients?

Yes. The 20 mg/mL oral solution is specifically important for pediatric administration because it supports body-surface-area-based dosing and avoids capsule-swallowing requirements [1].

Does Vitrakvi contain propylene glycol?

Yes. Propylene glycol is listed as an excipient in the Vitrakvi oral solution and functions primarily as a cosolvent and solubility aid [1].

Can a generic company copy the Vitrakvi oral solution?

A generic company may develop an equivalent oral solution, but it must satisfy applicable pharmaceutical equivalence, bioequivalence, stability, preservative, packaging, and device requirements. Listed patents and regulatory exclusivity can affect timing.

Is Vitrakvi a biologic with biosimilar competition?

No. Vitrakvi contains the small-molecule kinase inhibitor larotrectinib. Competition would generally arise through generic or hybrid regulatory pathways rather than biosimilar approval.

What is the strongest lifecycle-management opportunity for Vitrakvi?

An improved pediatric oral liquid is the strongest opportunity. The most commercially relevant attributes are taste masking, dosing precision, lower excipient burden, longer in-use stability, and a validated oral-syringe or feeding-tube presentation.

References

1. U.S. Food and Drug Administration. (2024). Vitrakvi (larotrectinib) prescribing information. https://labeling.bayerhealthcare.com/html/products/pi/vitrakvi/pi_vitrakvi.pdf

2. U.S. Food and Drug Administration. (2023). Rozlytrek (entrectinib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725s005lbl.pdf

3. U.S. Food and Drug Administration. (2023). Augtyro (repotrectinib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214766s000lbl.pdf

4. U.S. Food and Drug Administration. (2021). FDA grants regular approval to larotrectinib for solid tumors with NTRK gene fusion. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-larotrectinib-solid-tumors-ntrk-gene-fusion

5. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-designation-and-exclusivity

6. U.S. Food and Drug Administration. (2024). Hatch-Waxman Amendments and the Paragraph IV patent certification process. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

8. Bayer AG. (2013). Bayer and Loxo Oncology enter global license agreement for larotrectinib program. https://www.bayer.com/en/news-stories

9. Eli Lilly and Company. (2019). Lilly completes acquisition of Loxo Oncology. https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-loxo-oncology